Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK-011 plus atezolizumab or standard of care in advanced HCC
NCT05441475Phase 2Enrolling by invitation
- Sponsor
- Abbisko Therapeutics
- Start
- Dec 2021
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irpagratinib in hepatocellular carcinoma (HCC), sponsored by Abbisko Therapeutics. Started Dec 2021; status: enrolling by invitation.
02
Drugs
irpagratinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05441475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441475.